MGNX News and Press, MacroGenics Inc. From 06/02/21

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...

The "Tesla Test" looks for the rare combination of forensic scores that preceded a 40% drop in TSLA stock in a prior ad-hoc study forecasting many other stock declines since. This ongoing test of 22 adverse fundamental forensic and value ratios across four accounting algorithms resume...

Shares of MacroGenics (NASDAQ: MGNX) were tumbling 5.7% lower as of 11:39 a.m. EDT on Thursday. The decline came after the company announced preliminary results from its phase 1 study evaluating MGC018 in treating solid tumors. MacroGenics said that it saw preliminary signals of...

MacroGenics shares fall ([[MGNX]] -5.7%) after the company posted preliminary safety and anti-tumor activity data from its ongoing Phase 1 clinical trial of MGC018.A total of 29 patients with advanced solid tumors were enrolled in five dose escalation cohorts with MGC018 at 0.5 to 4.0 mg...

Dose escalation: anti-tumor activity observed in melanoma (including one confirmed partial response) and in mCRPC patients Cohort expansion in mCRPC: 11/22 (50%) patients have ≥ 50% PSA reduction; anti-tumor activity observed in four of seven patients evaluated ...

ROCKVILLE, MD, May 19, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will parti...

This relatively unknown pure-play on the emerging checkpoint LAG3 (Lymphocyte Activating Gene-3) has collaborations with Novartis, Merck, Pfizer, Merck KGaA, GlaxoSmithKline, EOC Pharma, Labcorp, etc. As clinical data continues to strengthen, Immutep is seemingly well situated for pot...

The following slide deck was published by MacroGenics, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: MacroGenics, Inc. 2021 Q1 - Results - Earnings Call Presentation

Image source: The Motley Fool. MacroGenics (NASDAQ: MGNX) Q1 2021 Earnings Call Apr 29, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: MacroGenics (MGNX) Q1 2021 Earnings Call Transcript

MacroGenics, Inc. (MGNX) Q1 2021 Earnings Conference Call April 29, 2021 16:30 ET Company Participants Anna Krassowska - Investor Relations Scott Koenig - President & Chief Executive Officer Jim Karrels - Senior Vice President & Chief Financial Officer Conference Call Participants Jon...